IMPORTANCE Protamine sulfate can be administered at the conclusion of carotid endarterectomy (CEA) to reverse the anticoagulant effects of heparin and to limit the risk for postoperative bleeding. Protamine use remains controversial owing to concern for increased thrombotic complications with its use.
arin is routinely administered to reduce thrombus formation during artery clamping. However, while heparin use is essentially universal, reversal of heparin with protamine is not. [7] [8] [9] Some surgeons reverse heparin with protamine at the conclusion of the procedure to limit bleeding; other surgeons do not, citing concern that protamine reversal increases the risk for thrombotic events, namely stroke.
Uncertainty about the risks of reversing heparin with protamine is reflected in ongoing variation of practice patterns. Studies have described up to 5-fold variation in the use of protamine, ranging from less than 20% of procedures to nearly 100% by surgeons. 8, 10 Concern for thrombotic complications with protamine use stems from early trials that showed increased risk for stroke with protamine. [11] [12] [13] However, several observational studies have failed to replicate this increase in stroke rates or other thrombotic complications among patients receiving protamine following carotid endarterectomy (CEA). [14] [15] [16] These studies showed a lower risk for bleeding when protamine was used, suggesting that protamine is effective in limiting the risk for bleeding after carotid surgery. Reported risks for bleeding during CEA vary as well, from 1.2% to 12%, owing in part to a lack of standardized definitions. 14, 17, 18 Determining whether protamine is associated with lower rates of bleeding after CEA is an important goal because bleeding carries significant risk for airway compromise or reoperationboth independent risk factors for perioperative mortality. 19 Therefore, we performed a meta-analysis of evidence relating both stroke and bleeding with protamine use in carotid artery revascularization. A better understanding of the relationships between protamine use, stroke, and bleeding across existing randomized and observational studies will help determine whether protamine use is justified in clinical practice. Because of limited literature regarding protamine in carotid stenting and the different nature of bleeding complications between stenting (at the access site) and surgery (in the neck), our quantitative analysis was limited to CEA.
Methods

Review Protocol
Prior to conducting the review, we outlined our planned approach to the identification and selection of the studies. MetaAnalyses of Observational Studies in Epidemiology guidelines were used to report methods and findings (eAppendix 1 in the Supplement). 20 The original protocol is available on request.
Study Eligibility Criteria
We aimed to include all studies that addressed the use of protamine in carotid revascularization. The following eligibility criteria were specified: (1) the design was a randomized clinical trial, retrospective or prospective cohort, nested casecontrol, before-and-after study, or secondary analysis of a randomized trial; (2) the population included adult patients undergoing any carotid procedures who were therapeutically anticoagulated with heparin; (3) the intervention/exposure was protamine sulfate to reverse heparin at the end of the procedure; (4) the comparison was no reversal of heparin; and (5) the study reported incidence of stroke during hospitalization. Our analysis focused on CEA, although we included the relevant stenting studies in the Table.
Outcome Measures
Stroke was the primary outcome of interest. Any type or severity of stroke was included in the analysis as long as it was diagnosed using objective criteria. Secondary outcomes included thromboembolic complications (death, myocardial infarction [MI] , and transient ischemic attack). To capture the potential benefits of protamine use, postoperative bleeding events were examined as a secondary outcome. Bleeding was defined as reoperation for bleeding.
Search Methods
With consultation from reference librarians, we searched electronic databases including Medline (1946 Medline ( -2014 , EMBASE (1966 EMBASE ( -2014 , and the Cochrane Library (1972-2014) during November 2014. By using MeSH terms and key words, we created sets for the various carotid procedures (CEA or carotid artery stenting) and the exposure (protamine). To find studies including both of these components, we used the Boolean term AND to combine the 2 sets. We used no limits or language restrictions (search strategies are in eAppendix 2 in the Supplement). Several strategies were used to identify unpublished, incomplete, or ongoing clinical trials. Two electronic trial registries were searched in October 2014: clinicaltrials.gov and International Clinical Trials Registry. Additionally, we hand searched the annual proceedings from the annual meetings of the Society for Vascular Surgery (2002 Surgery ( -2014 and the American Heart Association Scientific Sessions , as well as references of included articles in November 2014.
Two reviewers independently screened the titles and abstracts of all records. Obviously irrelevant studies were excluded. Two reviewers independently reviewed the remaining full-text articles and selected relevant studies based on our inclusion criteria. At least 2 reviewers independently extracted data from each eligible study. Additional information from principal investigators was sought as needed. All discrepancies were resolved by consensus. Reviewers were health researchers and physicians, in regular consultation with senior vascular surgeons. For articles and abstracts not in English, we relied on translation by native speaker colleagues at The Dartmouth Institute for Health Policy and Clinical Practice (Lebanon, New Hampshire).
Assessment of Risk for Bias
Two reviewers independently assessed the risk for bias using a modified version of the Newcastle-Ottawa Scale, which accommodates both observational studies and randomized trials. 27, 28 This scale consists of 3 categories: selection, comparability, and outcome, with questions in each domain cor-
Statistical Analysis
Relative risks (RRs) were used to summarize those studies amenable to quantitative pooling. Three otherwise eligible studies were excluded from the meta-analysis of stroke. 17, 18, 21 These studies did not specify whether the patients who experienced stroke had received protamine, and adequate data could not be obtained. As they otherwise met inclusion criteria, these studies were included when possible in the analysis of secondary outcomes.
Data Synthesis
Review Manager version 5.3 (Cochrane Collaboration) was used to calculate summary estimates using both fixed-and randomeffects models. Findings were reported based on randomeffects models to account for heterogeneity among treatment effects across studies.
Assessment of Heterogeneity
Heterogeneity among the study findings contributing to each summary was estimated based on Review Manager output. Excess heterogeneity was considered present if either the I 2 (inconsistency) was greater than 50% or the P value was less than .10 and identification of responsible studies was attempted. Both method and clinical characteristics of studies were examined for possible explanations. Summary estimates were recalculated based on the largest group of homogeneous studies that could be combined.
Assessment of Reporting Biases
To assess for evidence of publication bias, funnel plots of stroke and bleeding risk were created in Review Manager. Authors examined plots for an inappropriate correlation between sample size and effect size.
Subgroup Analyses
We had planned subgroup analysis by routine protamine use and use of dual antiplatelet agents prior to starting the analysis. However, we were unable to perform these analyses owing to a lack of usable data. A post hoc analysis of patch 
Sensitivity Analyses
Three analyses were prespecified to evaluate the impact of method quality on the overall summary estimates. First, because the studies were published over 2 decades, studies were stratified by year of publication (prior to 2000 and after 2000). Second, because there were several very large studies, studies were stratified by size (<1000 patients and >1000 patients). Last, components of the modified Newcastle-Ottawa Scale and summary estimates were recalculated and restricted to studies considered at low risk for bias. We compared whether the direction, magnitude, or statistical significance of the restricted summary estimates meaningfully differed from the overall estimates.
Results
Results of Search
As shown in Figure 1 , our search yielded 360 potentially relevant records. We excluded 217 based on title and abstract screening, and 129 based on full-text review. This left 14 studies that met all inclusion criteria: 12 related to CEA and 2 related to carotid stenting.
11-18,21-26
Included Studies
The 17 and a nested case-control. 18 Sample sizes ranged from 42 to 4587, and baseline characteristics, including age, sex, and race/ethnicity, were similar between the protamine and no protamine groups. When mentioned, goal activated clotting time ranged from 250 to 350 seconds. Between the 2 studies evaluating patients undergoing carotid stenting, one was a pooled analysis of data from 4 randomized trials, 25 while the other was a nested casecohort study. 26 Sample sizes were 2104 and 1110, respectively.
Baseline characteristics including age, sex, and race/ethnicity were again similar among the protamine and no protamine groups. As a whole, the patients in the carotid stenting studies were older than those in the endarterectomy studies (age range, 70-80 years vs 60-80 years, respectively) and less likely to receive protamine (8%-8.3% vs 10%-60%, respectively). We applied the modified Newcastle-Ottawa Scale to assess for the risk for bias among both randomized and nonrandomized trials. The most common risk for bias was related to the selection of experimental and control groups. In 5 studies, there was a risk that patients receiving protamine systematically differed from patients not receiving protamine. 11, 15, 18, 21, 24 Of these, 4 failed to describe the derivation of the protamine Pooling the study findings, the rate of perioperative stroke was 62 of 3907 (1.59%) among patients who received protamine and 122 of 6025 (2.02%) among those who did not receive protamine ( Figure 2A) . The weighted summary estimate demonstrated no significant differences between groups (RR, 0.84; 95% CI, 0.55-1.29). Heterogeneity among the trials was low (P = .31; I 2 = 15%), suggesting a consistent lack of difference in stroke risk between patients who received and did not receive protamine. These findings remained unchanged after sensitivity analyses to account for high risk for bias, older studies, or larger sample size. we performed a sensitivity analysis by study design. Two excluded studies using a single-surgeon study design 11, 15 created a statistically homogenous group, which showed similar bleeding risk reduction for patients given protamine (RR, 0.57; 95% CI, 0.39-0.84; I 2 = 32%) ( Figure 3 ).
Eleven studies provided data on the risk for any bleeding events, which included wound hematomas and requirement of transfusion. [11] [12] [13] [14] [15] [16] [17] [18] 21, 23, 24 Again, the use of protamine was associated with a significantly lower rate of bleeding events (RR, 0.46; 95% CI, 0.38-0.73). As in the outcome of bleeding requiring reoperation, the test of heterogeneity was again borderline (P = .07; I 2 = 42%). Sensitivity analysis was performed by study design and excluded 2 studies using a single-surgeon study design to create a statistically homogenous group, with similar effect (RR, 0.52; 95% CI, 0.38-0.73; P = .20; I 2 = 27%).
Other Outcomes: All-Cause Mortality and Myocardial Infarction
Seven studies reported data on all-cause mortality among patients undergoing CEA. [14] [15] [16] ( Figure 2B and C).
Subgroup Analyses
We were able to perform a post hoc analysis of stroke risk in studies using 2 characteristics of surgical processes of care during CEA: shunt use and patch angioplasty. Three studies had data stratified by patch and shunt use. 11, 13, 23 Protamine use was not associated with an increased risk for stroke in the patch angioplasty or shunt subgroups ( Figure 4 ).
Sensitivity Analyses
We performed sensitivity analyses, using only those studies with high-quality score/low risk for bias within each domain of the Newcastle-Ottawa Scale (selection, comparability, and exposure). This did not meaningfully alter the study findings for stroke. Within each restricted analysis, the findings between the protamine and no protamine groups did not differ significantly. Additional sensitivity analyses based on study age (published before 2000) or sample size (excluding the largest studies) did not meaningfully change the risk for stroke (full analysis shown in eAppendix 4 in the Supplement). After repeating these restricted analyses for the major bleeding outcome, all 7 restricted estimates continued to favor protamine and 5 remained statistically significant. When findings were restricted to only those studies published after 2000, there was no change in stroke risk with protamine use. However, the benefit of protamine for decreasing bleeding was not significant when restricted only to studies published after 2000 or to larger studies, although these analyses had heterogeneity (I 2 = 60% and I 2 = 76%, respectively), which could not be eliminated through further sensitivity analyses.
Publication Bias
We found no evidence of publication bias based on the funnel plot for stroke. However, we noted that all published small studies strongly favored protamine with regard to the major bleeding outcome (eFigure 1 and eFigure 2 in the Supplement). 
Discussion
We performed a meta-analysis of 12 studies, which included 9932 patients, 3907 (40%) of whom received protamine and 6025 (61%) of whom did not. We found that the use of protamine in CEA was not associated with a statistically significant increase in the risk for stroke. Additionally, protamine use was not related to a higher risk for any other thromboembolic complications, such as MI or death. However, protamine use was associated with a 43% decline in major bleeding risk. These findings were consistent across studies spanning several decades and remained unchanged when restricted to studies considered to be at low risk for bias.
A key aspect of any meta-analysis is the quality of the evidence. In our study, the quality of the included studies varied for several reasons. First, 11 of our 12 studies were observational in nature, and confounding may be a concern within these studies. [12] [13] [14] [15] [16] [17] [18] [21] [22] [23] [24] We were able to perform a subgroup analysis of measured confounders, such as differences in operative technique, which did not change our primary finding. Second, because the studies spanned over a 20-year period, our findings were limited by temporal trends that have occurred. Overall stroke risk was higher in the older studies than in the newer studies (2.7% vs 1.7%; P = .002), as was bleeding risk (4.6% vs 1.7%; P < .001). We suspect this decline in adverse outcomes reflects improvements in patient selection, medical therapy, and preoperative management. Third, there Mauney et al, 13 Test for overall effect: z = 1.87 (P = .06) performed in academic centers, so these findings may not be replicable across smaller private hospitals. However, 2 of the studies were single-surgeon trials 11, 15 and the largest database included all levels of hospitals, 14 which allows the findings to be applicable to all surgeon practices. The risk for bias was considered low overall, based on our assessment tool. The lack of heterogeneity in stroke and bleeding rates across studies, as well as the lack of between-study differences in other outcomes (transient ischemic attack, MI, and death) suggests that our findings reflect a real effect across a range of study designs and settings.
We minimized the possibility of missing trials using multiple methods to search both published and unpublished literature. Furthermore, contact with several study authors did not reveal any additional unpublished data on the topic. We were limited by missing data for the primary outcome, despite attempted contact with the 3 authors whose stroke outcome was not stratified by protamine use. 17, 18, 21 That noted,
we performed analysis with all strokes for each study occurring within the protamine arm, and our main finding remained unchanged. Stroke remains a difficult outcome to standardize owing to differing definitions across studies. Our study was no exception: we were unable to discern thromboembolic from other stroke etiologies, as authors often included all perioperative stroke. However, hemorrhagic stroke during CEA is not thought to be associated with procedural factors, and so the rate should be equally distributed across both groups. Furthermore, hypotension due to protamine reaction has been cited as a possible etiology for stroke: no included study included patients who experienced protamine reaction. 30, 31 A second difficulty in studying stroke risk is that as it becomes increasingly rare following CEA, differences related to protamine use are more difficult to discern. This trend is unlikely to have biased our findings, as our findings were stable across sensitivity analyses of older and newer studies. Furthermore, our study of protamine use in CEA had similar findings to previously published meta-analyses of the use of protamine in coronary angioplasty, which found no increased risk of stroke. 32 Finally, the trials included in our analysis varied widely with regard to operative technique and patient characteristics. Despite this, diversity did not affect heterogeneity on our main outcome measure: stroke. Given the wide variety of clinical practice in CEA, both in operative technique and preoperative medical management, we think this study is more representative of the use of protamine in a realworld environment.
Other potential sources of bias in our meta-analysis might include the broad inclusion criteria, limited randomized clinical trials, lack of studies that included other procedures, inability to explore subgroups that might have explained heterogeneity, and the varied definitions for bleeding complications across studies. We performed analyses with both narrow and broad definitions of bleeding, and the benefit of protamine use remained unchanged.
Conclusions
Our study has important implications. Surgeons should consider routinely using protamine during CEA owing to the decreased risk for bleeding with its use. While the net reduction in bleeding complications is small, reoperation for any reason after CEA has the potential for increased morbidity. Given that there were fewer studies examining protamine use in carotid artery stenting, further research on protamine and carotid stenting is needed to determine whether our findings are consistent across all types of carotid revascularization.
